David Mold

Title: David Mold: Innovator in Pharmaceutical Formulations

Introduction

David Mold is a notable inventor based in Baltimore, MD (US), recognized for his contributions to pharmaceutical formulations. He holds a total of four patents, focusing on innovative treatments for various neoplastic diseases. His work has significant implications for cancer therapy, particularly in enhancing humoral immunity.

Latest Patents

Mold's latest patents include formulations of terameprocol and temozolomide, which are designed to stimulate humoral immunity in tumors. This invention provides novel pharmaceutical formulations comprising derivatives of NDGA, including MN (tetra-0-methyl nordihydroguaiaretic acid) and temozolomide. These formulations are aimed at inhibiting and treating neoplastic diseases, such as glioblastoma multiforme, lung cancer, and other malignancies. Another significant patent involves compositions comprising NDGA derivatives and sorafenib, which are utilized in the treatment of various cancers, including liver, colon, breast, brain, and ovarian cancers. This patent also includes combinations of NDGA derivatives, sorafenib, and additional therapeutic agents.

Career Highlights

Throughout his career, David Mold has worked with prestigious institutions, including The Johns Hopkins University and Erimos Pharmaceuticals, LLC. His experience in these organizations has allowed him to develop groundbreaking pharmaceutical solutions that address critical health challenges.

Collaborations

Mold has collaborated with esteemed colleagues, including Ru Chih C Huang and Yu-Chuan Liang, contributing to the advancement of cancer treatment through innovative research and development.

Conclusion

David Mold's work in pharmaceutical formulations exemplifies the impact of innovation in the medical field. His patents reflect a commitment to improving cancer therapies and enhancing patient outcomes.